Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Mitiglinide
Introduction
Overview
Overview
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.[1]
Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Pharmacology
Pharmacology
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.
Dosage
Dosage
Mitiglinide is delivered in tablet form.
References
References
- ↑ Malaisse WJ (October 2008). “Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients”. Expert Opin Pharmacother. 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455.
External links
External links
- Elixir Pharmaceuticals – website of the U.S. rights holder for mitiglinide.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]